Thank you, Fred. BIO-key’s total Q3 2018 revenue decreased 21.5% to $740,000 from $942,000 in Q3 2017, due to lower fingerprint hardware and biometric lock sales, as well as lower service revenue related to the timing of certain products. Gross margin was negatively impacted as non-cash software license amortization expense rose from $660,000 -- rose to $660,000 in Q3 ‘18, compared to $390,000 in Q3 ‘17. Excluding the software license amortization costs, BIO-key’s Q3 ‘18 gross margin would have increased to 62% versus the 43% in Q3 ‘17, with the difference largely due to the revenue mix that included more high margin software license revenue in Q3 ‘18 versus the prior year period. Total operating expenses declined $184,000 or 11% to $1.4 million, due to lower selling, general and administrative costs. Lower operating costs relating to primary -- primarily to lower personnel compensation in Q3 ‘18, as well as the absence the NASDAQ uplisting costs that were incurred in Q3 ‘17. During Q3 ‘18 BIO-key incurred a one-time non-cash expense of $0.4 million related to the modification of outstanding warrants, which were re-priced in connection with our common stock and warrant offering, which I will discuss more in a moment. Including the warrant modification expense, BIO-key’s Q3 net loss available to common stockholders was $3.1 million or a loss of $0.23 per basic share versus a net loss available to common shareholders of $1.8 million or a loss of $0.28 per share in Q3 ‘17. Per share results are based on approximately 13.1 million and 6.5 million weighted average basic shares outstanding in Q3 ‘18 and Q3 ‘17, respectively. In August, we completed an underwritten offering of common shares and warrants at a purchase price of $1.50 per unit. The offering was intended to support the company’s working capital needs and growth initiative. Net proceeds from the offering were approximately $1.8 million. As a result of the non-dilutive provisions related to the existing outstanding currents stock options, the recent common stock offering required that we re-price certain warrants in conjunction with the offering. As a result of lowering -- the lowering of the strike price at certain warrants BIO-key recorded a $1.4 million in non-cash warrant modification expense in the third quarter of 2018. BIO-key’s net working capital remains constant at $4.7 million as of both September 30, 2018 and December 31, 2017. Net working capital included approximately $1 million of cash and cash equivalents at the close of the third quarter 2018 versus $289,000 of cash at year end 2017. And with that, I think, we can move on to questions. Operator, could you please start the question-and-answer period.